[{"orgOrder":0,"company":"Bioniz Therapeutics","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"BNZ-1","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bioniz Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioniz Therapeutics \/ Almirall","highestDevelopmentStatusID":"7","companyTruncated":"Bioniz Therapeutics \/ Almirall"},{"orgOrder":0,"company":"Bioniz Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"BNZ-1","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bioniz Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioniz Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bioniz Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bioniz Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"BNZ-1","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Bioniz Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioniz Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bioniz Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Bioniz Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The deal would expand Almirall's R&D pipeline with an additional three candidates on top of lead drug BNZ-1.

                          Product Name : BNZ132-1-40

                          Product Type : Peptide

                          Upfront Cash : $15.0 million

                          September 01, 2020

                          Lead Product(s) : BNZ-1

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Almirall

                          Deal Size : $62.0 million

                          Deal Type : Collaboration

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : This study followed a phase 1/2, multi-center, open-label, dose-escalation clinical study of BNZ-1 and was designed to assess its safety and activity as a single systemic agent in rCTCL patients that have failed standard of care and other available treat...

                          Product Name : BNZ132-1-40

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          July 20, 2020

                          Lead Product(s) : BNZ-1

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : These data are the first to show therapeutic efficacy of BNZ-1, a multi-cytokine inhibitor selectively targeting three interleukins, IL-2, IL-9, and IL-15. In the study, BNZ-1 treatment was well tolerated with no dose-limiting toxicities or drug-related ...

                          Product Name : BNZ132-1-40

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          May 11, 2020

                          Lead Product(s) : BNZ-1

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank